SCBIHEALT(SSFE) invests in the master fund BNP Paribas Funds Health Care Innovators (Luxembourg). Actual total expense ratio (TER) 0.11% a year. Has a dividend policy. Data as of 13 Nov 2026.
SCB Healthcare Innovation
Shows where this fund stands in its group. Not investment advice · Data as of 16 Nov 2026
SCBIHEALT(SSFE) invests through the master fund BNP Paribas Funds Health Care Innovators 98.77%
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per BNP Paribas fact sheet
Over the past year it was above its group median; over 3 years it returned +9.40% per year (Above the median)
| Return | SD | MDD | Return/SD | |
|---|---|---|---|---|
| YTD | +14.75% | −13.55% | ||
| 1D | +0.32% | 0.00% | ||
| 1W | +2.04% | −0.77% | ||
| 2W | +1.91% | −2.28% | ||
| 1M | +10.37% | −2.28% | ||
| 3M | +11.44% | −5.87% | ||
| 6M | +24.25% | −7.03% | ||
| 1Y | +15.66% | 17.25% | −14.67% | +0.91 |
| 3Y | +30.95%+9.40%/yr | 17.93% | −21.53% | +0.52 |
| MAX | +0.03%+0.01%/yr | 21.65% | −42.76% | +0.00 |
| Return | MDD | SD | Return/SD | |
|---|---|---|---|---|
| YTD | +14.75% | −13.55% | ||
| 1D | +0.32% | 0.00% | ||
| 1W | +2.04% | −0.77% |
Past performance is not a guarantee of future results
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −3.3 | +0.8 | −3.7 | −2.8 | +2.9 | +7.4 | −1.4 | +4.9 |
Largest drawdown in the selected period −42.76% Previous peak 16 Aug 2022 (NAV 6.3569) → Trough 8 Aug 2025 (NAV 3.6388) · Not back to the previous peak as of 13 Nov 2026
Currently −19.38% from the peak NAV of 6.3569 (16 Aug 2022)
Over 3 years, SCBIHEALT(SSFE) returned 0.52 per unit of SD, ranking 28 of 57 funds · The highest is TBIOTECH (0.94)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว (Feeder Fund) ได้แก่ กองทุน BNP Paribas Funds Health Care Innovators - Class I Capitalisation (กองทุนหลัก) ในสกุลเงินยูโร (EUR) Its largest holdings are หน่วยลงทุน BNP HEALTH CARE INNOV-I 98.77% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 10 Jun 2022, its NAV has fallen as much as −42.76% from its peak.
Actual total expense ratio (TER) 0.11% a year, against a ceiling of 1.83%. Management fee 0.00%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
It has a dividend policy but has not paid any dividends yet
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 82.39% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · SCBIHEALT(SSFE): pays dividends, TER 0.11% · SCBIHEALTH(A): no dividends, TER 1.71% · SCBIHEALTH(D): see the conditions in the prospectus · SCBIHEALTH(E): no dividends, TER 0.11% · SCBIHEALTH(IN): see the conditions in the prospectus · SCBIHEALTH(P): no dividends, TER 0.10% · SCBIHEALTH(R): see the conditions in the prospectus · SCBIHEALTH(SSF): pays dividends, TER 1.71%
SCBIHEALTH(A) · SCBIHEALTH(E) · SCBIHEALTH(P) · SCBIHEALTH(SSF)
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Diabetes and weight-loss drugs
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
A US drug company making HIV treatment and prevention drugs, hepatitis drugs and cancer drugs
Based on the master fund's share of this fund's value (98.77% as of 31 Aug 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from BNP Paribas · Illustrations are for explanation only, not individual stock recommendations
| ฿1,000 |
| SCBIHEALTH(E) | None | No | 0.11% | 0.00% | ฿1 |
| SCBIHEALTH(P) | None | No | 0.10% | N/A | N/A |
| SCBIHEALTH(SSF) | Pays | SSF | 1.71% | 0.00% | ฿1,000 |
| 2W | +1.91% | −2.28% |
| 1M | +10.37% | −2.28% |
| 3M | +11.44% | −5.87% |
| 6M | +24.25% | −7.03% |
| 1Y | +15.66% | −14.67% | 17.25% | +0.91 |
| 3Y | +30.95%+9.40%/yr | −21.53% | 17.93% | +0.52 |
| MAX | +0.03%+0.01%/yr | −42.76% | 21.65% | +0.00 |
No. 1 is SCBGENOME(E) +49.91%
No. 1 is TBIOTECH +23.13% per year
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 16 Nov 2026
| −0.4 |
| +8.3 |
| +1.9 |
| · |
| +14.8* |
| 2025 | +5.7 | +0.4 | −8.4 | −5.8 | −4.1 | −1.2 | +1.3 | +2.4 | +1.6 | +9.8 | +7.8 | −3.8 | +4.2 |
|---|
| 2024 | −3.4 | +2.0 | +3.1 | −6.7 | −1.2 | +3.0 | −0.0 | +2.1 | −1.6 | −2.6 | +5.0 | −5.3 | −5.9 |
|---|
| 2023 | +3.2 | −6.0 | +0.3 | +1.3 | −2.1 | +0.2 | +3.6 | −10.7 | −9.9 | −12.7 | +7.6 | +10.3 | −16.5 |
|---|
| 2022 | · | · | · | · | · | +1.1 | +7.7 | +1.9 | −6.8 | +2.1 | +2.4 | −1.5 | +6.4* |
|---|
| Average | +0.6 | −0.7 | −2.2 | −3.5 | −1.1 | +2.1 | +2.3 | +0.1 | −3.4 | +1.0 | +4.9 | −0.0 | −6.1 |
|---|